Biogen (BIIB) PT Raised to $320 at Barclays
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $204.05 -0.8%
Rating Summary:
26 Buy, 17 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 18 | New: 43
Rating Summary:
26 Buy, 17 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 18 | New: 43
Join SI Premium – FREE
Barclays raised its price target on Biogen (NASDAQ: BIIB) to $320.00 (from $295.00) while maintaining a Equalweight rating.
Analyst Geoff Meacham believes good Q2 results from Tuesday should provide downside support for the equity in Wednesday's trading session should the BAN2401 presentation not meet what he calls Street expectations. The analyst raises his estimates and thus his target price.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DigitalOcean (DOCN) PT Lowered to $155 at UBS Following Pre-Announced Q2 Results
- Biogen (BIIB) PT Lowered to $222 at Morgan Stanley
- BTIG Starts Presidio Production (FTW) at Buy
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst PT ChangeRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
